L3VLUP
ProSign in

BDX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BDXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BDX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBDXLLY
Q3 202025 holders, $11.3bn33 holders, $14.1bn
Q4 202028 holders, $10.4bn29 holders, $17.3bn
Q1 202126 holders, $9.4bn24 holders, $23.0bn
Q2 202119 holders, $9.0bn24 holders, $27.8bn
Q3 202118 holders, $10.3bn31 holders, $29.9bn
Q4 202118 holders, $11.1bn31 holders, $34.7bn
Q1 202221 holders, $10.5bn24 holders, $35.3bn
Q2 202221 holders, $13.5bn33 holders, $42.7bn
Q3 202223 holders, $11.0bn31 holders, $43.4bn
Q4 202227 holders, $12.5bn31 holders, $46.6bn
Q1 202328 holders, $11.1bn33 holders, $44.3bn
Q2 202326 holders, $11.7bn37 holders, $59.6bn
Q3 202323 holders, $10.3bn44 holders, $67.6bn
Q4 202327 holders, $8.7bn45 holders, $73.6bn
Q1 202425 holders, $8.4bn41 holders, $95.3bn
Q2 202431 holders, $8.1bn43 holders, $110bn
Q3 202426 holders, $8.6bn45 holders, $107bn
Q4 202426 holders, $8.4bn46 holders, $93.9bn
Q1 202522 holders, $8.6bn42 holders, $98.4bn
Q2 202524 holders, $7.3bn43 holders, $93.2bn
Q3 202513 holders, $7.3bn39 holders, $86.7bn
Q4 202517 holders, $8.6bn41 holders, $123bn
Q1 202615 holders, $8.5bn39 holders, $106bn
Q2 202611 holders, $8.4bn44 holders, $132bn
BDX

Becton Dickinson & Co

Holders
22
Reported value
$8.6bn
Buyers
12
Sellers
11

Breadth +1 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
42
Reported value
$98.4bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 49 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BDX (7)

D1 Capital Partners LP, ExodusPoint Capital Management LP, First Eagle Investment Management LLC, Harris Associates LP, Starboard Value LP, Two Sigma Investments LP, Walleye Capital LLC

Only LLY (27)

Acadian Asset Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Coatue Management LLC, D. E. Shaw & Co., Egerton Capital UK LLP, Eisler Capital Management Ltd, Element Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Lone Pine Capital LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tiger Global Management LLC, Tudor Investment Corp, Two Sigma Advisers LP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →